相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer
Matthew R. Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors
Atish D. Choudhury et al.
CLINICAL CANCER RESEARCH (2022)
Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer
Christopher J. Sweeney et al.
CLINICAL CANCER RESEARCH (2022)
Smart Nanoparticles as Advanced Anti-Akt Kinase Delivery Systems for Pancreatic Cancer Therapy
Juan Gonzalez-Valdivieso et al.
ACS APPLIED MATERIALS & INTERFACES (2021)
Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update
Katherine S. Virgo et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer
Thanakorn Pungsrinont et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial
S. Dent et al.
ANNALS OF ONCOLOGY (2021)
A phase I study of capivasertib in combination with abiraterone acetate in patients with metastatic castration-resistant prostate cancer.
Neal D. Shore et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
BKM120 sensitizes BRCA-proficient triple negative breast cancer cells to olaparib through regulating FOXM1 and Exo1 expression
Yu Li et al.
SCIENTIFIC REPORTS (2021)
Rapamycin-Loaded Lipid Nanocapsules Induce Selective Inhibition of the mTORC1-Signaling Pathway in Glioblastoma Cells
Delphine Sehedic et al.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY (2021)
Synergistic Inhibition of Drug-Resistant Colon Cancer Growth with PI3K/mTOR Dual Inhibitor BEZ235 and Nano-Emulsioned Paclitaxel via Reducing Multidrug Resistance and Promoting Apoptosis
Yali Hu et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2021)
A phase Ib study of enzalutamide (Enza) plus CC-115 in men with metastatic castration-resistant prostate cancer (mCRPC)
J. L. Zhao et al.
ANNALS OF ONCOLOGY (2021)
A phase III trial with a 2x2 factorial design in men with de novo metastatic castration-sensitive prostate cancer: Overall survival with abiraterone acetate plus prednisone in PEACE-1
K. Fizazi et al.
ANNALS OF ONCOLOGY (2021)
A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3K beta Inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
Debashis Sarker et al.
CLINICAL CANCER RESEARCH (2021)
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Oliver Sartor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers
Ninghui Mao et al.
NATURE COMMUNICATIONS (2021)
Tissue- and Blood-derived Genomic Biomarkers for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review
Kim Van der Eecken et al.
EUROPEAN UROLOGY ONCOLOGY (2021)
Phase 2 clinical trial of TORC1 inhibition with everolimus in men with metastatic castration-resistant prostate cancer
Daniel J. George et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2020)
A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer
M. P. Kolinsky et al.
ANNALS OF ONCOLOGY (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Emerging role of PTEN loss in evasion of the immune response to tumours
Thiago Vidotto et al.
BRITISH JOURNAL OF CANCER (2020)
Deregulated PTEN/PI3K/AKT/mTOR signaling in prostate cancer: Still a potential druggable target?
Luca Braglia et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2020)
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
Maha Hussain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Divergent Roles of PI3K Isoforms in PTEN-Deficient Glioblastomas
Shaozhen Xie et al.
CELL REPORTS (2020)
The PTEN Conundrum: How to Target PTEN-Deficient Prostate Cancer
Daniel J. Turnham et al.
CELLS (2020)
Low dose novel PARP-PI3K inhibition via nanoformulation improves colorectal cancer immunoradiotherapy
M. R. Landry et al.
MATERIALS TODAY BIO (2020)
Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss
Johann S. de Bono et al.
CLINICAL CANCER RESEARCH (2019)
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205
Sebastien J. Hotte et al.
CLINICAL GENITOURINARY CANCER (2019)
Abiraterone acetate plus prednisone in patients with newly Croatia& diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial
Karim Fizazi et al.
LANCET ONCOLOGY (2019)
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
Fabrice Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Bioanalysis of Targeted Nanoparticles in Monkey Plasma via LC-MS/MS
Wei Song et al.
ANALYTICAL CHEMISTRY (2019)
Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer
Adam Sharp et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation
Yan Xing et al.
BREAST CANCER RESEARCH (2019)
Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing
Srinivas R. Viswanathan et al.
CELL (2018)
A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors
Carol Aghajanian et al.
INVESTIGATIONAL NEW DRUGS (2018)
A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer
Laura Graham et al.
INVESTIGATIONAL NEW DRUGS (2018)
The long tail of oncogenic drivers in prostate cancer
Joshua Armenia et al.
NATURE GENETICS (2018)
Clinical implications of PTEN loss in prostate cancer
Tamara Jamaspishvili et al.
NATURE REVIEWS UROLOGY (2018)
PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux
Jake S. O'Donnell et al.
SEMINARS IN CANCER BIOLOGY (2018)
Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer in combination to PARP inhibition
Rania El Botty et al.
Oncotarget (2018)
PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses
Jiqing Sai et al.
CLINICAL CANCER RESEARCH (2017)
Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer
Christophe Massard et al.
EUROPEAN JOURNAL OF CANCER (2017)
Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer
Andrew J. Armstrong et al.
EUROPEAN JOURNAL OF CANCER (2017)
Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma
Suzanne George et al.
IMMUNITY (2017)
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Karim Fizazi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate Cancer
Xiao X. Wei et al.
ONCOLOGIST (2017)
Efficacy and safety of BRAF inhibition alone versus combined BRAF and MEK inhibition in melanoma: a meta-analysis of randomized controlled trials
Mengdong Liu et al.
ONCOTARGET (2017)
mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer
Wei Mo et al.
CLINICAL CANCER RESEARCH (2016)
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
Weiyi Peng et al.
CANCER DISCOVERY (2016)
A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer
Helen Chow et al.
CANCER (2016)
Genomic Approaches to Understanding Response and Resistance to Immunotherapy
David A. Braun et al.
CLINICAL CANCER RESEARCH (2016)
A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer
Thomas Powles et al.
EUROPEAN UROLOGY (2016)
Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth
Michele C. Smith et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Targeting therapeutic liabilities engendered by PIK3R1 mutations for cancer treatment
Lydia W. T. Cheung et al.
PHARMACOGENOMICS (2016)
Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer
Christine Henzler et al.
NATURE COMMUNICATIONS (2016)
Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy
Klaus Okkenhaug et al.
CANCER DISCOVERY (2016)
Feedback Suppression of PI3Kα Signaling in PTEN-Mutated Tumors Is Relieved by Selective Inhibition of PI3Kβ
Sarit Schwartz et al.
CANCER CELL (2015)
Integrative Clinical Genomics of Advanced Prostate Cancer
Dan Robinson et al.
CELL (2015)
The Molecular Taxonomy of Primary Prostate Cancer
Adam Abeshouse et al.
CELL (2015)
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Charles J. Ryan et al.
LANCET ONCOLOGY (2015)
Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel
Urs Hancox et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Dual PI3K/mTOR Inhibitor NVP-BEZ235 Sensitizes Docetaxel in Castration Resistant Prostate Cancer
Yota Yasumizu et al.
JOURNAL OF UROLOGY (2014)
Idelalisib - A PI3Kδ Inhibitor for B-Cell Cancers
David A. Fruman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy REPLY
Tomasz M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
T. M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-naive castration-resistant prostate cancer
K. Kruczek et al.
BRITISH JOURNAL OF CANCER (2013)
Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC)
Hielke J. Meulenbeld et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
A Phase II Trial of Temsirolimus in Men With Castration-Resistant Metastatic Prostate Cancer
Andrew J. Armstrong et al.
CLINICAL GENITOURINARY CANCER (2013)
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
C. Parker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The evolution of the TOR pathway and its role in cancer
E. M. Beauchamp et al.
ONCOGENE (2013)
Both p110α and p110β isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor
Inma M. Berenjeno et al.
BIOCHEMICAL JOURNAL (2012)
Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer
Mari Nakabayashi et al.
BJU INTERNATIONAL (2012)
Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas
Piro Lito et al.
CANCER CELL (2012)
mTOR Signaling in Growth Control and Disease
Mathieu Laplante et al.
CELL (2012)
Safety and Preliminary Efficacy Analysis of the mTOR Inhibitor Ridaforolimus in Patients With Taxane-Treated, Castration-Resistant Prostate Cancer
Robert J. Amato et al.
CLINICAL GENITOURINARY CANCER (2012)
The p110α and p110β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis
Tamara Utermark et al.
GENES & DEVELOPMENT (2012)
Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
Barry R. Davies et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The Promise of Combining Inhibition of PI3K and PARP as Cancer Therapy
Farah L. Rehman et al.
CANCER DISCOVERY (2012)
PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
Yasir H. Ibrahim et al.
CANCER DISCOVERY (2012)
Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
Ashish Juvekar et al.
CANCER DISCOVERY (2012)
Functional Characterization of an Isoform-Selective Inhibitor of PI3K-p110β as a Potential Anticancer Agent
Jing Ni et al.
CANCER DISCOVERY (2012)
Cell Autonomous Role of PTEN in Regulating Castration-Resistant Prostate Cancer Growth
David J. Mulholland et al.
CANCER CELL (2011)
Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
Brett S. Carver et al.
CANCER CELL (2011)
Decreased Expression and Androgen Regulation of the Tumor Suppressor Gene INPP4B in Prostate Cancer
Myles C. Hodgson et al.
CANCER RESEARCH (2011)
Long-Term Androgen Ablation and Docetaxel Up-Regulate Phosphorylated Akt in Castration Resistant Prostate Cancer
Takeo Kosaka et al.
JOURNAL OF UROLOGY (2011)
WWP2 is an E3 ubiquitin ligase for PTEN
Subbareddy Maddika et al.
NATURE CELL BIOLOGY (2011)
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. De Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Phosphoinositide 3-Kinase Pathway Activation in Phosphate and Tensin Homolog (PTEN)-deficient Prostate Cancer Cells Is Independent of Receptor Tyrosine Kinases and Mediated by the p110β and p110δ Catalytic Subunits
Xinnong Jiang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
Johann Sebastian de Bono et al.
LANCET (2010)
The emerging mechanisms of isoform-specific PI3K signalling
Bart Vanhaesebroeck et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
CCL2 Is Induced by Chemotherapy and Protects Prostate Cancer Cells From Docetaxel-Induced Cytotoxicity
David Z. Qian et al.
PROSTATE (2010)
A complex interplay between Akt, TSC2 and the two mTOR complexes
Jingxiang Huang et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2009)
The Akt kinases Isoform specificity in metabolism and cancer
Eva Gonzalez et al.
CELL CYCLE (2009)
Essential roles of PI(3)K-p110β in cell growth, metabolism and tumorigenesis
Shidong Jia et al.
NATURE (2008)
Post-translational regulation of PTEN
X. Wang et al.
ONCOGENE (2008)
PTEN-deficient cancers depend on PIK3CB
Susan Wee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
The p110α isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation
Jean J. Zhao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Oncogenic transformation induced by the p110β, -γ, and -δ isoforms of class I phosphoinositide 3-kinase
S Kang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
The oncogenic properties of mutant p110α and p110β phosphatidylinositol 3-kinases in human mammary epithelial cells
JJ Zhao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Phosphatidylinositol 3′-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells
JT Lee et al.
CANCER RESEARCH (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
分享论文
